Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.

导出 LinkOut

翻译打印收藏纠错

作者： Vivek,Kumar ^[1] ; Neha,Chaudhary ^[2] ; Mohit,Garg ^[1] ; Charalampos S,Floudas ^[1] ; Parita,Soni ^[1] ; Abhinav B,Chandra ^[3]

作者单位： Department of Medicine, Maimonides Medical Center Brooklyn, NY, USA. ^[1] Department of Pediatrics, Maimonides Medical Center Brooklyn, NY, USA. ^[2] Medical Director, Yuma Regional Cancer Center Yuma, AZ, USA. ^[3]

关键词 checkpoint blockade immune related adverse events ipilimumab irAEs nivolumab pembrolizumab

DOI 10.3389/fphar.2017.00049

PMID 28228726

发布时间 2022-03-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览54

Frontiers in pharmacology

2017年8卷

49页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除